Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLG | P54098 | 2/20 | 0.59 |
| ▸ | POLA1 | P09884 | 2/20 | 0.56 |
| ▸ | P2RY2 | P41231 | 10/20 | 0.56 |
| ▸ | P2RY4 | P51582 | 6/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | P2RY6 | Q15077 | 5/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.48 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16665344 | 1.00 | POLG (0.59) | POLGPOLA1P2RY2P2RY4POLB | |
| SCHEMBL16644560 | 0.91 | POLG (0.57) | POLGPOLA1P2RY2P2RY4POLB | |
| SCHEMBL16368334 | 0.91 | POLG (0.57) | POLGPOLA1P2RY2P2RY4POLB | |
| SCHEMBL16566201 | 0.91 | POLA1 (0.69) | POLGPOLA1P2RY2P2RY4POLB | |
| SCHEMBL16777764 | 0.91 | POLA1 (0.69) | POLGPOLA1P2RY2P2RY4POLB | |
| SCHEMBL16777865 | 0.91 | POLA1 (0.69) | POLGPOLA1P2RY2P2RY4POLB | |
| SCHEMBL19352290 | 0.89 | POLG (0.58) | POLGPOLA1P2RY2P2RY4POLB | |
| Gemcitabine Triphosphate SCHEMBL5598638 | 0.89 | POLA1 (0.69) | POLGPOLA1P2RY2P2RY4POLB | |
| SCHEMBL4576237 | 0.89 | POLG (0.59) | POLGPOLA1P2RY2P2RY4POLB | |
| Gemcitabine Triphosphate SCHEMBL15160598 | 0.89 | POLA1 (0.69) | POLGPOLA1P2RY2P2RY4POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170198005-A1 | 2'-DICHLORO AND 2'-FLUORO-2'-CHLORO NUCLEOSIDE ANALOGUES FOR HCV INFECTION | IDENIX PHARMACEUTICALS LLC (US) | 2017-07-13 | — | — | US | disclosed |
| US-20170198005-A1 | 2'-DICHLORO AND 2'-FLUORO-2'-CHLORO NUCLEOSIDE ANALOGUES FOR HCV INFECTION | IDENIX PHARMACEUTICALS LLC (US) | 2017-07-13 | — | — | US | disclosed |
| US-20160271160-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2016-09-22 | — | — | US | disclosed |
| US-20160271160-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2016-09-22 | — | — | US | disclosed |
| US-20160271160-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2016-09-22 | — | — | US | disclosed |
| WO-2015081297-A1 | 2'-DICHLORO AND 2'-FLUORO-2'-CHLORO NUCLEOSIDE ANALOGUES FOR HCV INFECTION | IDENIX PHARMACEUTICALS, INC. (US) | 2015-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160271160-A1 | HCV POLYMERASE INHIBITORS | POLI, POLB, POLL | POLG 29/4885POLA1 13/4885P2RY2 880/4885 |
| US-20170198005-A1 | 2'-DICHLORO AND 2'-FLUORO-2'-CHLORO NUCLEOSIDE ANALOGUES FOR HCV INFECTION | HAVCR2, SLC29A2, SLC28A2 | POLG 755/4885POLA1 276/4885P2RY2 984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.